GlassScriptPhysician profile
Hernando Torres Ortiz
NPI 1073038923
$3,887.85
in general payments reported to CMS, 2019-2025
23 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $48.30 · 2021: $993 · 2022: $48.30 · 2023: $354 · 2024: $1,052 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $727.93 | 2024-2025 | |
| Astellas Pharma US INC | $532.95 | 2019-2021 | |
| Amgen INC. | $495.58 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $239.55 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $216.11 | 2021-2025 | Watchman Flx |
| Pfizer INC. | $198.50 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $190.49 | 2024 | Arcalyst |
| Viiv Healthcare Company | $124.99 | 2019 | |
| Allergan, INC. | $124.99 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.74 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $115.73 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $114.36 | 2021-2025 | Wainua, Lokelma, Farxiga |
| Alexion Pharmaceuticals, INC. | $113.97 | 2021 | |
| Alnylam Pharmaceuticals INC. | $111.93 | 2023-2024 | Onpattro |
| Merck Sharp & Dohme LLC | $75.17 | 2020-2024 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71.57 | 2025 | |
| Myriad Genetic Laboratories, INC. | $70.69 | 2024-2025 | Prolaris |
| Medtronic, INC. | $63.27 | 2022-2023 | Corevalve Evolut R |
| Kiniksa Pharmaceuticals, LTD. | $55.82 | 2023 | Arcalyst |
| Exact Sciences Corporation | $50.97 | 2023-2024 | Cologuard Collection Kit |
| Terumo Medical Corporation | $28.67 | 2020 | |
| Novo Nordisk INC | $23.81 | 2025 | Wegovy |
| Abbott Laboratories | $23.06 | 2025 | Freestyle Libre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernando Torres Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.